Education
About Us
Working with TipRanks
Follow Us
Context Therapeutics (CNTX)
NASDAQ:CNTX
CNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.49 - $2.59
Previous CloseN/A
Volume293.07K
Average Volume (3M)182.82K
Market Cap
$85.55M
Enterprise Value-$20.98M
Total Cash (Recent Filing)$83.52M
Total Debt (Recent Filing)$167.32K
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 05, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding89,704,190
10 Day Avg. Volume225,678
30 Day Avg. Volume182,818
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.16K
Enterprise Value/Ebitda0.56
Forecast
1Y Price Target
$4.50Price Target Upside394.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical ProgressContext Therapeutics is making progress on its two T cell engaging bispecific antibodies for solid tumors, CTIM-76 and CT-95, which are currently in Phase 1 dose-escalation trials.
Competitive AdvantageLead asset CTIM-76 has the potential to address a clinically de-risked target with best-in-class efficacy and safety.
Strategic DevelopmentContext Therapeutics is advancing a platform of T cell engaging bispecifics for solid tumors, which is viewed as a growing sub-category within oncology with strong clinical, commercial, and strategic momentum.
Bears Say
Market PressureCNTX shares have been pressured driven mainly by continued, challenging biotech markets and lack of catalysts as management has focused on building its portfolio.
Trial TimelineThe trial for CTIM-76 is sufficiently enrolling patients across its 8 active sites and is on track to deliver initial dose-escalation data in mid-2026.
Context Therapeutics News
CNTX FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was $0.49 and its highest was $2.59 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is $85.55M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 39 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.062 by -$0.028.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 89,704,190 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.062. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in CNTX
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (394.51% Upside)
$4.50 (394.51% Upside)
Blogger Sentiment
Bullish
CNTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 681.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-53.21%
12-Months-Change
Fundamentals
Return on Equity
-37.25%
Trailing 12-Months
Asset Growth
-15.15%
Trailing 12-Months
Company Description
Context Therapeutics
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
CNTX Stock 12 Month Forecast
Average Price Target
$4.50
▲(394.51% Upside)
Technical Analysis
Ownership Overview
1.38% Insiders
5.96% Mutual Funds
65.45% Other Institutional Investors
23.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---